Octapharma

Octapharma USA, also known as Octapharma Plasma USA and simply Octapharma, is engaged in the collection of human plasma and the subsequent manufacture of plasma‑derived therapeutic proteins. These products are used to treat patients with immunodeficiency disorders, bleeding conditions, and other serious medical needs that rely on plasma‑based medicines. The organization operates a network of plasma donation centers throughout the United States, where donors contribute plasma that is later fractionated into therapeutic agents. In addition to its U.S. collection activities, Octapharma maintains European production sites, including German donation centers and manufacturing facilities, which support its global supply chain. Its core mission centers on ensuring a safe and reliable supply of plasma‑derived medicines for patients worldwide.

The source material does not provide explicit quantitative details about the organization’s size, such as the number of donation centers, employees, annual plasma volume, or revenue figures. Consequently, any description of scale must be omitted rather than inferred or guessed. The absence of stated metrics means that the profile can only reflect the qualitative aspects of Octapharma USA’s operations that are directly mentioned in the available information. This limitation ensures that the description remains strictly factual and avoids speculation about the company’s footprint or market share.

Distinguishing attributes of Octapharma USA include its specialized focus on plasma‑derived therapeutics and its demonstrated capacity to activate incident response protocols swiftly, as evidenced by the temporary suspension of U.S. plasma donation center operations following detected suspicious network activity on April 17, 2024. The incident highlighted a segregated operational structure, whereby European facilities continued normal operations while U.S. centers were shut down to contain potential impacts, reflecting a robust business continuity and crisis management capability. The organization’s emphasis on maintaining stringent regulatory compliance across its collection and manufacturing sites underscores its commitment to product safety and quality. Its ability to coordinate a rapid, organization‑wide response while preserving uninterrupted service in other regions illustrates a notable competency in operational resilience and risk management.

Structural notes indicate that Octapharma USA operates under the broader Octapharma brand, with the U.S. activities specifically identified as Octapharma Plasma USA. The aliases provided show that the organization is recognized both by its geographic designation and by the parent company name, suggesting a subsidiary relationship without explicit ownership details in the source material. No further information regarding parent‑subsidiary structure, ownership stakes, or corporate governance is supplied in the available context. Therefore, the profile concludes with the confirmed fact that the U.S. operation is branded as Octapharma Plasma USA and is part of the Octapharma organization.